<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-112 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-112</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-112</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <p><strong>Paper ID:</strong> paper-81b2a6652a8fde71493fde504f0e7da1b55abf89</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/81b2a6652a8fde71493fde504f0e7da1b55abf89" target="_blank">Spatial and temporal diversity in genomic instability processes defines lung cancer evolution</a></p>
                <p><strong>Paper Venue:</strong> Science</p>
                <p><strong>Paper TL;DR:</strong> 25 spatially distinct regions from seven operable NSCLCs were sequenced and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification, and pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC cytidine deaminase activity.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e112.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e112.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOBEC</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>APOBEC cytidine deaminase–mediated mutagenesis (including APOBEC3B)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An endogenous cytidine deaminase mutational process (C>T and C>G at TpC trinucleotides) that is enriched in subclonal/late mutations in many LUAD samples and is associated with generation of subclonal driver mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Multiregion whole-exome and whole-genome sequencing (M-seq WES/WGS) with transcript (mRNA) expression measurement in regions</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven surgically resected NSCLC patients (25 spatially distinct tumor regions sequenced); cohort included LUAD and LUSC cases. The study did not define or report a percentage of cases labeled specifically as 'driver-negative' for RTK/RAS/RAF.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>APOBEC-mediated mutagenesis / APOBEC3B up-regulation as a mutational mechanism generating subclonal driver mutations</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Endogenous mutational mechanism (enzymatic mutagenesis); indirectly genetic via resulting point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>APOBEC-signature mutations (C>T and C>G at TpC) were significantly enriched on branches (late/subclonal mutations) versus trunk (clonal) in 4/5 LUAD M-seq samples; on average 31% (range 8–41%) of nonsilent branch mutations occurred in an APOBEC context vs 11% (7–16%) of truncal nonsilent mutations. Several subclonal driver mutations (PIK3CA, EP300, TGFBR1, PTPRD, AKAP9) occurred in an APOBEC context. TCGA LUAD tumors with detectable APOBEC signatures showed significant enrichment of late APOBEC mutations (P < 0.001). Regional heterogeneity in APOBEC mRNA expression (APOBEC3B highest in an APOBEC-enriched region) supports activity of the process.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>The temporal APOBEC enrichment trend was less clear or absent in TCGA LUSC tumors with detectable APOBEC signatures, indicating histology-dependent differences; enrichment is correlative (signature and expression) without direct functional validation that APOBEC activity is required for expansion of the subclones observed.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>APOBEC activity is a late-acting endogenous mutational process in many LUADs that creates a pool of subclonal mutations, including functionally relevant driver mutations, thereby driving subclonal diversification and evolution after initial tumor initiation.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e112.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Genome doubling (WGD) / CIN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Whole-genome doubling and chromosomal instability (CIN)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Genome-doubling events and ongoing chromosomal instability that increase copy-number heterogeneity and provide substrate for rapid genomic evolution and subclonal diversification.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>High-coverage M-seq whole-genome sequencing and copy-number analysis; fluorescence in situ hybridization (FISH) for numerical chromosomal diversity</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven NSCLC patients (25 regions); four tumors displayed evidence of genome doubling. No subgroup labeled 'driver-negative' specified.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Whole-genome doubling followed by chromosomal instability as a mechanism accelerating tumor evolution and generating heterogeneous driver copy-number events</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Large-scale genetic/structural genomic alteration (aneuploidy, ploidy change) and genome instability</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Four tumors showed genome-doubling events; in three (L001, L004, L008) the doubling preceded regional diversification and the majority of truncal mutations (84–88%) were present at ploidy ≥2, indicating doubling after early mutation accumulation. Subclonal copy-number aberrations were observed within regions (e.g., >15% of genome in L008 R1). Centromeric FISH confirmed numerical chromosomal diversity within regions, and structural variant analyses revealed complex rearrangement patterns (chained translocations) consistent with punctuated chromosomal events.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Genome doubling and CIN were observed variably across the cohort (not universal); while associated with increased heterogeneity and linked in other work to resistance, this study provides correlative temporal placement rather than functional causation proving WGD drives recurrence or therapy resistance in these samples.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Genome doubling occurs after early driver acquisition and then accelerates chromosomal instability, producing copy-number heterogeneity and enabling subclonal competition and rapid acquisition of additional driver events.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e112.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PI3K (PIK3CA)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PI3K pathway — PIK3CA E542K (subclonal) / pathway activation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activating mutation in PIK3CA found regionally/subclonally (E542K), representing an alternative oncogenic driver that can coexist with or replace canonical RTK/RAS/RAF drivers in some regions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Multiregion whole-exome sequencing with mutation annotation</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven NSCLC patients (25 regions); specific example: L008 had activating BRAF (G469A) truncal and activating PIK3CA (E542K) present only in region R3; no explicit driver-negative count provided.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>PIK3CA activating mutation (E542K) driving regional tumor cell populations via PI3K pathway activation</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation activating a signaling pathway (oncogene)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>PIK3CA E542K was detected only in region R3 of patient L008, while BRAF G469A was truncal; the regional PIK3CA mutation implies a subclonal activating event that could drive local populations and affect therapeutic sensitivity (paper discusses potential resistance to BRAF inhibitors).</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>PIK3CA was regionally restricted (not truncal) in the described tumor, indicating it is not the founding driver in that case; absence of functional validation in this study for oncogenicity in this tumor context (but PIK3CA E542K is a known activating mutation from other literature).</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>PI3K pathway activation via subclonal PIK3CA mutations can act as an alternative driver in tumor subpopulations and mediate regional differences in therapeutic vulnerabilities when canonical RTK/RAS/RAF events are absent or heterogeneous.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e112.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Structural variants / chromoanagenesis (NF1, FANCM)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Chromoanagenesis-like chained translocations disrupting tumor suppressors (e.g., NF1, FANCM)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Highly clustered chained translocations and complex rearrangements (indicative of chromoanagenesis) that disrupt tumor suppressors such as NF1 and FANCM, representing non-point-mutation genetic drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>High-coverage M-seq whole-genome sequencing with structural variant breakpoint analysis</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven NSCLC tumors with two tumors (L002, L008) analyzed by M-seq WGS at mean 96× coverage; in L008, chained translocations between chromosomes disrupted FANCM and NF1.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Disruption of tumor suppressor genes (NF1, FANCM) by complex structural rearrangements (chained translocations) as driver events</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Structural genomic alterations (translocations, deletions) disrupting tumor suppressors</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>In L008, 48 of 52 structural variants were shared between regions; chained translocations with highly clustered breakpoints disrupted FANCM and NF1. Breakpoint homology profiling suggested nonhomologous or alternative end-joining consistent with double-strand break events and chromoanagenesis, implying simultaneous acquisition of multiple oncogenic events.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>The observation comes from one tumor (L008) in this cohort; broader recurrence across LUAD not demonstrated within this study, and direct functional demonstration that these specific rearrangements drive tumorigenesis in these samples was not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Punctuated catastrophic rearrangement events (chromoanagenesis) can produce multiple driver-altering lesions simultaneously, including loss of tumor suppressor function, contributing to tumor evolution independent of canonical RTK/RAS/RAF point mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e112.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tumor suppressor CNAs (CDKN2A, PTEN)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Copy-number loss of tumor suppressors such as CDKN2A and PTEN</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Focal or regional homozygous/heterozygous deletions of tumor suppressor loci (CDKN2A, PTEN) observed as truncal or heterogeneous events that can drive cell-cycle deregulation and PI3K pathway activation respectively.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Integer copy-number estimation from M-seq WES/WGS and regional comparison with TCGA recurrent segments</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven NSCLC patients; copy-number changes analyzed across 25 tumor regions. No explicit 'driver-negative' stratification provided.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Loss of CDKN2A and PTEN by copy-number deletion as alternative driver mechanisms in regions lacking canonical RTK/RAS/RAF alterations</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic — copy-number alteration (deletion) affecting tumor suppressors</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>CDKN2A (chr9p21.3) and PTEN (chr10q23.31) deletions were observed as truncal in L001 (present in all regions) and heterogeneous in L008, indicating regionalized loss of tumor suppressors. Many recurrent TCGA segments were found to be heterogeneous in at least one tumor region in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Heterogeneous occurrence means deletions are not universally truncal across tumors; functional consequences in these specific regions were not directly assayed in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Regional loss of tumor suppressors via CNAs can provide local selective advantage and act as alternative drivers in subclonal populations when canonical oncogenic drivers are absent or heterogeneous.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e112.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Other subclonal driver genes</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Subclonal point mutations in driver genes (EP300, TGFBR1, PTPRD, AKAP9, FAT1, ZFHX4, ARHGAP35)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multiple non-RTK/RAS/RAF driver genes were found mutated in a subclonal or region-specific manner, suggesting alternative genetic routes to regional oncogenicity in LUAD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Multiregion whole-exome sequencing (M-seq WES) with driver annotation</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven NSCLC patients (25 regions); mutations in listed genes were observed as branch-specific in various tumors (e.g., TGFBR1, PTPRD, EP300, AKAP9 in LUAD region of L002; FAT1 in LUSC branch). No driver-negative percentage provided.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Mutations in genes such as EP300 (epigenetic regulator), TGFBR1 (TGF-β receptor), PTPRD (tyrosine phosphatase), AKAP9, FAT1, ZFHX4, ARHGAP35 as subclonal drivers in regional tumor populations</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic point mutations affecting signaling, epigenetic regulation, or cell architecture (oncogenic or tumor-suppressive alterations)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Specific branch/private driver mutations were detected: e.g., in L002 LUAD region mutations in TGFBR1 and PTPRD occurred in an APOBEC context; EP300 and AKAP9 were also recorded as branched driver genes. L002 had truncal TP53 and CHD8 mutations. These are observed by high-coverage sequencing and placed temporally on phylogenetic trees.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Many of these events are subclonal and region-restricted (not truncal), so they are not universal founding drivers; the study provides sequence-based evidence but no direct functional assays in these samples to prove driver activity.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>LUAD tumors can evolve alternative subclonal driver events in diverse genes (signaling receptors, epigenetic regulators, phosphatases) that promote local expansion and may substitute for or cooperate with canonical drivers in different tumor regions.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e112.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Smoking mutational signature</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tobacco smoke–associated mutational signature (C>A transversions)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Exogenous mutational process producing C>A transversions; predominant in truncal/early mutations in smokers and former smokers, indicating early carcinogenic exposure and initiation context.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Temporal dissection of point-mutation spectra from multiregion WES/WGS and validation in TCGA LUAD/LUSC cohorts</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Seven M-seq NSCLCs (25 regions) analyzed for temporal mutation spectra; validated across TCGA LUAD and LUSC cohorts stratified by smoking status. No explicit driver-negative definition.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Early-stage tobacco carcinogen exposure as the initiating mutational process producing truncal driver mutations in many LUADs (even in former smokers decades after exposure)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Exogenous mutational process (environmental carcinogen footprint) leading to genetic driver mutations</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>All tumors showed a statistically significant decrease in the proportion of C>A transversions in late vs early mutations (P < 0.05). In M-seq and TCGA LUAD/LUSC, current and former smokers showed decreased C>A in late mutations (e.g., LUAD current/former smokers P < 0.0001). Truncal driver mutations and genome-doubling events were often placed within a smoking-signature context, even in patients who ceased smoking >20 years before surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>A decrease in smoking-signature mutations over time implies other processes (e.g., APOBEC) contribute later; presence of smoking signature does not specify which specific driver mutations are caused by tobacco; never-smoker samples did not show the same trends.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Tobacco carcinogens act early to generate the initial mutational burden and founding driver mutations, after which other processes (APOBEC, CIN) contribute to progression and subclonal evolution.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e112.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e112.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immune microenvironment</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Adaptive immune system / tumor-immune engagement (microenvironmental factor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The authors propose leveraging the adaptable immune system to manage intratumor heterogeneity and dynamic subclonal architecture in NSCLC as a therapeutic strategy rather than a molecular driver per se.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Discussion-level suggestion; no immune profiling performed in this study</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Not applicable beyond the seven NSCLC tumors profiled genomically; immune composition was not assayed in this work.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Not proposed as a molecular driver; suggested as a microenvironmental/therapeutic axis to control heterogeneous subclones (i.e., engaging immune system to manage dynamic tumor complexity).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Microenvironmental / immunological (therapeutic approach rather than a genetic driver)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Authors note that the presence of subclonal regionally separated driver events and ongoing genomic instability complicates targeted therapy; they propose that an adaptable immune response may better control heterogeneous tumors — this is a conceptual suggestion rather than data driven from this study.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>No immune profiling, functional or clinical data in this paper to support efficacy of immune engagement for these specific cases; suggestion is speculative within the discussion.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Because of pervasive intratumor heterogeneity driven by diverse genomic instability processes, targeting single truncal genetic drivers may be insufficient; a broad adaptive immune response might control multiple subclones concurrently.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Science. 2014 October 10; 346(6206):251–256. doi:10.1126/science.1253462.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Spatial and temporal diversity in genomic instability processes defines lung cancer evolution', 'publication_date_yy_mm': '2014-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <p class="empty-note">No potentially relevant new papers extracted.</p>
        </div>

        </div>

    </div>
</body>
</html>